Overall survival from the open label phase 2 trial of palbociclib in patients with advanced well differentiated/dedifferentiated liposarcoma. An update on the results ...

Real-world experience with vorasidenib in IDH-mutant gliomas: Tolerability, adverse events, and access in patients who did not meet INDIGO trial eligibility criteria. This is an ASCO Meeting Abstract ...

Circadian disruption, occurring in shift work, sleep deprivation, or dementia, increases the risk of sarcopenia, the age-related loss of muscle mass and strength. The cell-intrinsic and extrinsic ...